These findings highlight the potential therapeutic advantage of a combination approach targeting both JAK/STAT signaling and the antiapoptotic proteins Bcl-2/Bcl-xL in patients with ATLL [60]. This evidence concerns the gene BCL2 and adult T-cell leukemia/lymphoma.